PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

NASCAR will hold a street race on Naval Base Coronado in Southern California next June as a replacement for its downtown ...

Today’s stock market focus is centered on one single sector: technology stocks. The excitement around artificial intelligence ...

Police reports from the Idaho murders case are shedding new light on the investigation into Bryan Kohberger after he killed four students in their off-campus apartment.

The exanthema market is projected to grow from USD 1.39 billion in 2024 to USD 2.51 billion by 2034 at a CAGR of 6.10%. This growth is driven by risi ...

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

The final weekend of July is packed with events honoring some of the people who have had an impact on the sport of auto ...

Pharmaceutical giant Pfizer recently shared its plans to revive vaccine awareness in Mexico and become a key vaccine supplier ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Last Saturday’s 25th annual Seek the Peak hike-a-thon surpassed the $250,000 fundraising goal for the non-profit, ...

The cancer pain market, valued at USD 6.53 billion in 2024, is projected to reach USD 11.81 billion by 2034, with a CAGR of 6 ...